Early access
Sign in
Taking people in GermanyPhase 3

Daily ASC30 pill compared with placebo in adults with obesity or overweight

Tests daily oral ASC30 against placebo for weight loss in adults.

Key facts

Who runs it
Ascletis Pharma (China) Co. Ltd.
Where
Berlin, Essen, Hanover, and Leipzig, GermanySee the 5 sitesAlso in 3 other countries, 39 sites
Registry title
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
Status
Recruiting
Phase
Phase 3
People taking part
932 people, planned
Started
7 Oct 2026
Expected to end
15 Oct 2028
Type of study
Interventional
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity, or with overweight and a weight-related health problem, who tried to lose weight with diet at least once without success.

Age
18 years or older (or the legal age of consent locally).
Sex
All sexes can join.
Disease stage
BMI 30 kg/m² or more, or BMI 27 kg/m² or more with at least one weight-related condition such as cardiovascular disease, high blood pressure, abnormal blood fats or obstructive sleep apnea.
Earlier treatment
At least one earlier diet attempt to lose weight that did not work.

Main reasons for not taking part

  • Any diabetes (type 1, type 2 or other), or a history of ketoacidosis or hyperosmolar state/coma
  • Body weight change of more than 5 kg (11 lb) within 3 months before screening
  • Past or present pancreatitis (acute or chronic)
  • Personal or close family history of medullary thyroid carcinoma or MEN syndrome type 2
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • 1-Be able to provide signed informed consent and comply with study requirements
  • 2-Be ≥18 years old (or legal age of consent locally)
  • 3-Have: BMI ≥30 kg/m², or 4-BMI ≥27 kg/m² with at least one weight-related comorbidity such as: cardiovascular disease, hypertension, dyslipidemia, or obstructive sleep apnea
  • 5-Have at least one prior unsuccessful dietary weight-loss attempt
  • 6-Not be pregnant or breastfeeding; contraception requirements apply per local regulations

Who cannot take part

  • Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma. Participants with a history of gestational diabetes are eligible to participate in this trial. Have a self-reported change in body weight >5 kg (11 pounds) within 3 months prior to screening; 2.Have a history of acute or chronic pancreatitis any time prior to screening
  • Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2. "

Where in Germany

Also in 3 other countries, 39 sites

  • FutureMeds GmbHBerlin, GermanyTaking people
  • Velocity Clinical Research Germany GmbHBerlin, GermanyTaking people
  • Praxis Am MarktEssen, GermanyTaking people
  • Klinische Forschung Hannover-Mitte GmbHHanover, GermanyTaking people
  • Ambenet GmbH Das Ambulante BehandlungsnetzLeipzig, GermanyTaking people

About the trial

What the trial wants to find out

To demonstrate that dose 1 , dose 2 , and/or dose 3 pooled doses of once-daily oral ASC30 is superior to placebo From baseline to Week 72 in: Body weight

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily oral ASC30 in Adult Participants with Obesity or Overweight with Weight-Related Comorbidities (AURORA-1)
Plain-language title
Daily ASC30 pill compared with placebo in adults with obesity or overweightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
29 October 2026